Lupin launches generic equivalent of Depen Tablets
Mumbai: Global pharma major, Lupin Limited, today announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilson's disease, Cystinuria, and...
Mumbai: Global pharma major, Lupin Limited, today announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilson's disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Penicillamine Tablets USP, 250 mg (RLD: Depen®) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).
Read also: Lupin gets USFDA nod for generic equivalent of Northera Capsules
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd